oxybutynin has been researched along with Chronic Disease in 14 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "TY-0201 (TY) is a transdermal formulation of bisoprolol that is the free base of bisoprolol fumarate (BO), a drug widely used to treat chronic heart failure (CHF)." | 9.24 | Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure. ( Daimon, M; Dohi, N; Kinugawa, K; Komuro, I; Momomura, SI; Okamoto, H; Saito, Y; Sakata, Y; Yamamoto, K; Yasumura, Y, 2017) |
| "This article reviews the pharmacology, therapeutic efficacy and tolerability profile of the 7-day lower-dose (5, 10 and 20 μg/h) buprenorphine transdermal patch (BuTrans®, Norspan®) in the management of chronic non-malignant pain, with a focus on European labelling for the drug." | 8.87 | Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. ( Plosker, GL, 2011) |
| "Patients with chronic cancer pain were randomly assigned to the conversion from continuous intravenous infusion to transdermal fentanyl using two-step taper of the continuous intravenous infusion in 12 h (12-h method) or the conversion in 6 h (6-h method)." | 6.76 | Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study. ( Hayashi, K; Kamata, M; Kojima, H; Kozai, M; Nomura, M; Sawada, S, 2011) |
| "TY-0201 (TY) is a transdermal formulation of bisoprolol that is the free base of bisoprolol fumarate (BO), a drug widely used to treat chronic heart failure (CHF)." | 5.24 | Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure. ( Daimon, M; Dohi, N; Kinugawa, K; Komuro, I; Momomura, SI; Okamoto, H; Saito, Y; Sakata, Y; Yamamoto, K; Yasumura, Y, 2017) |
| "This article reviews the pharmacology, therapeutic efficacy and tolerability profile of the 7-day lower-dose (5, 10 and 20 μg/h) buprenorphine transdermal patch (BuTrans®, Norspan®) in the management of chronic non-malignant pain, with a focus on European labelling for the drug." | 4.87 | Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. ( Plosker, GL, 2011) |
| " We analyzed data from 5 open-label clinical trials of lidocaine patch 5% in osteoarthritis knee pain and chronic low back pain that were 2 to 12 weeks in duration." | 3.77 | Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events. ( Dworkin, RH; Galer, BS; Gammaitoni, AR; Gould, E; Jensen, MP; Jones, BA; Xiang, Q, 2011) |
| " Various retrospective studies comparing dosage changes of buprenorphine and fentanyl patches in persistent pain patients have been completed; however, no long-term prospective, randomized, clinical study has compared the effectiveness of these patches." | 2.78 | A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. ( Chowdhury, S; Mitra, F; Shelley, M; Williams, G, 2013) |
| "Patients with chronic cancer pain were randomly assigned to the conversion from continuous intravenous infusion to transdermal fentanyl using two-step taper of the continuous intravenous infusion in 12 h (12-h method) or the conversion in 6 h (6-h method)." | 2.76 | Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study. ( Hayashi, K; Kamata, M; Kojima, H; Kozai, M; Nomura, M; Sawada, S, 2011) |
| " The AMs used to treat OAB differ in their pharmacological profiles, which may affect their potential for causing adverse effects (AEs)." | 2.48 | Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. ( Alessandri, F; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Origoni, M; Remorgida, V; Salvatore, S; Venturini, PL, 2012) |
| "Chronic bacterial prostatitis was diagnosed in 15 patients (20." | 1.29 | Ten years experience with chronic prostatitis in Africans. ( Magoha, GA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, CC | 2 |
| Jiang, YH | 1 |
| Kuo, HC | 1 |
| Leone Roberti Maggiore, U | 1 |
| Salvatore, S | 1 |
| Alessandri, F | 1 |
| Remorgida, V | 1 |
| Origoni, M | 1 |
| Candiani, M | 1 |
| Venturini, PL | 1 |
| Ferrero, S | 1 |
| Listernick, R | 1 |
| Magoha, GA | 1 |
| Momomura, SI | 1 |
| Saito, Y | 1 |
| Yasumura, Y | 1 |
| Yamamoto, K | 1 |
| Sakata, Y | 1 |
| Daimon, M | 1 |
| Kinugawa, K | 1 |
| Okamoto, H | 1 |
| Dohi, N | 1 |
| Komuro, I | 1 |
| Jiang, H | 1 |
| Ochoa, M | 1 |
| Waimin, JF | 1 |
| Rahimi, R | 1 |
| Ziaie, B | 1 |
| Zhou, F | 1 |
| Wu, HJ | 1 |
| Zhai, JP | 1 |
| Zhang, GY | 1 |
| Shao, Y | 1 |
| Tian, X | 1 |
| Xia, RY | 1 |
| Jia, LY | 1 |
| Li, WY | 1 |
| Liang, N | 1 |
| Yan, XY | 1 |
| Wu, RH | 1 |
| Zhang, K | 1 |
| Li, XL | 1 |
| Liu, JP | 1 |
| Nomura, M | 1 |
| Kamata, M | 1 |
| Kojima, H | 1 |
| Hayashi, K | 1 |
| Kozai, M | 1 |
| Sawada, S | 1 |
| Park, JH | 1 |
| Kim, JH | 1 |
| Yun, SC | 1 |
| Roh, SW | 1 |
| Rhim, SC | 1 |
| Kim, CJ | 1 |
| Jeon, SR | 1 |
| Dworkin, RH | 1 |
| Jensen, MP | 1 |
| Gould, E | 1 |
| Jones, BA | 1 |
| Xiang, Q | 1 |
| Galer, BS | 1 |
| Gammaitoni, AR | 1 |
| Barkin, RL | 1 |
| Barkin, SJ | 1 |
| Irving, GA | 1 |
| Gordon, A | 1 |
| Plosker, GL | 1 |
| Mitra, F | 1 |
| Chowdhury, S | 1 |
| Shelley, M | 1 |
| Williams, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison Study of a Low-Fat Diet Supplemented With Fish Oil and a Standard Western Diet in Individuals With Prostate Cancer[NCT00798876] | 56 participants (Actual) | Interventional | 2001-12-18 | Completed | |||
| Evaluation in Efficacy and Safety of Fentanyl-TTS (Durogesic® D-Trans) for Treatment of Chronic Pain[NCT01902524] | Phase 4 | 65 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for oxybutynin and Chronic Disease
| Article | Year |
|---|---|
Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Chronic Disease; Cresols; Drug Combinations; Female; | 2012 |
Management of chronic noncancer pain in depressed patients.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, N | 2011 |
Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Disease; Dose-Response Relationship, Drug; Humans; Pain; | 2011 |
5 trials available for oxybutynin and Chronic Disease
| Article | Year |
|---|---|
Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder.
Topics: Aged; Aged, 80 and over; Chronic Disease; Drug Administration Schedule; Drug Therapy, Combination; F | 2017 |
Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Asian People; Bisoprolol; Chronic Disease; Fema | 2017 |
Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Chronic Disease; Double-Blind Method; Female; F | 2011 |
Evaluation of efficacy and safety of fentanyl transdermal patch (Durogesic D-TRANS) in chronic pain.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Female; Fentanyl; Humans; Male; | 2011 |
A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Chronic Disease; Chronic Pain; | 2013 |
6 other studies available for oxybutynin and Chronic Disease
| Article | Year |
|---|---|
A thirteen-year-old girl with anemia.
Topics: Adolescent; Anemia; Chronic Disease; Constipation; Encopresis; Enuresis; Female; Humans; Mandelic Ac | 2003 |
Ten years experience with chronic prostatitis in Africans.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Humans; Keny | 1996 |
A pH-regulated drug delivery dermal patch for targeting infected regions in chronic wounds.
Topics: Anti-Bacterial Agents; Bacterial Infections; Chronic Disease; Drug Delivery Systems; Drug Liberation | 2019 |
Who are the users of a traditional Chinese sanfu acupoint herbal patching therapy in China?: A cross-sectional survey.
Topics: Acupuncture Points; Adolescent; Adult; Age Factors; Aged; Ambulatory Care; Analysis of Variance; Art | 2016 |
Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events.
Topics: Anesthetics, Local; Chronic Disease; Clinical Trials as Topic; Female; Humans; Lidocaine; Low Back P | 2011 |
I just started using a fentanyl patch for chronic back pain. What special precautions should I take?
Topics: Administration, Cutaneous; Analgesics, Opioid; Back Pain; Chronic Disease; Fentanyl; Humans; Patient | 2012 |